Caris Life Sciences

November is Lung Cancer Awareness Month, a time to share stories of hope and progress. When Edwin Asturizaga was diagnosed with stage IV lung cancer, he nearly lost hope. But after turning to Caris for molecular profiling, things changed. Discover how advanced insights into his cancer helped transform his treatment plan. ow.ly/534Q51058v5

Caris Life Sciences announced that the first patients have been enrolled in a prospective, real-world observational study evaluating Caris ChromoSeq™, a Whole Genome Sequencing (WGS) assay designed to provide comprehensive genomic characterization of myeloid malignancies through a single integrated workflow. "Oncology has embraced comprehensive molecular profiling, yet patients with myeloid malignancies are often still evaluated through a fragmented testing process that requires multiple assays and workflows. Caris ChromoSeq was developed to challenge that paradigm,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. Learn more: ow.ly/r7ZB5105CR3

Caris is joining the molecular diagnostics community at the Association for Molecular Pathology (@AMPath) Annual Meeting and Expo. Visit Booth #600 to connect and learn how comprehensive DNA, RNA and protein analysis help advance precision oncology and personalized patient care. Learn more: ow.ly/HxaA5105xuG

Breadth and depth shouldn’t be a tradeoff —especially when patients need to know exactly what they’re fighting. Caris Assure® pairs the breadth of its 23,000+ gene Whole Exome Sequencing (WES) backbone with therapy-focused depth (up to 40,000x), helping clinicians identify actionable alterations from blood. Learn more: ow.ly/V9He51057U1

50 billion molecular markers. 1 million+ real patient cases. Caris Detect™ applies advanced AI trained on one of the largest oncological datasets of its kind to deliver early-stage cancer detection from a single blood draw. Order the test: CarisDetect.com

Caris Life Sciences announced the publication of a study in Clinical Cancer Research that used comprehensive molecular profiling to identify important biological differences among ESR1-mutated breast tumors and examine their association with time on treatment among patients receiving elacestrant. “This study highlights the complexity that exists within biomarkers that are often considered binary,” said Caris Chief Medical Officer George W. Sledge, Jr., MD, lead author of the study. Learn more: ow.ly/zobQ5104JC4

Join Caris at the @isliquidbiopsy ISLB 2026 and connect with the global liquid biopsy community. Visit Booth 5 to explore how comprehensive molecular profiling and liquid biopsy technologies are helping advance biomarker discovery, precision oncology and personalized treatment strategies. Learn more: ow.ly/kCgx5104ILv

Myeloid malignancies are genetically complex and often require multiple assays. Caris ChromoSeq brings the full genomic landscape into one high-coverage Whole Genome Sequencing (WGS) test, supporting clearer diagnosis and risk stratification in a single report. Learn more: bit.ly/4ufznZw

The stage at which cancer is diagnosed shapes outcomes. For certain cancers, five-year survival rate can exceed 90% at Stage I and fall below 10% at Stage IV. Caris Detect™ is a blood-based test designed to identify early-stage cancer signals, so patients can act sooner and increase there chances of survival. Order the test: CarisDetect.com

Caris Life Sciences released its third-quarter financial results today, which included revenue growth of 27% and raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29%. Learn more: ow.ly/sq8a5103S1v

When tumor heterogeneity raises questions, are you confident in the risk assessment? In a recent case of invasive lobular carcinoma, two distinct tumor regions showed discordant 21-gene assay scores. Caris MI Clarity™ evaluated two distinct tumor blocks and produced concordant early- and late-risk classifications, providing greater confidence that the reported risk reflected the patient's underlying disease risk. Learn more about how MI Clarity helped answer a challenging clinical question: ow.ly/QA3t50ZHLwL

Caris is heading to Chicago for the LUGPA 2026 Annual Meeting! Visit booth 109 to connect with our team and explore how comprehensive molecular profiling can help inform personalized treatment decisions for patients with genitourinary cancers. We look forward to seeing you there!

MI Cancer Seek® integrates Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) in a single assay to provide comprehensive genomic insights alongside FDA-approved CDx for solid tumors that help inform treatment strategies. Learn more: bit.ly/4lyGNTR

Connect with Caris at the Society for Immunotherapy of Cancer (@sitcancer) 2026 Annual Meeting. Visit booth #615 and discover how we're helping advance cancer immunotherapy through innovative molecular profiling solutions and comprehensive molecular insights. Learn more: ow.ly/nUB45101TLB #SITC26

Caris Detect™ is a blood test designed to find cancer in early stages, when treatment is most effective and survival rates are highest. Take a proactive step for your health today — get the answers you need to move forward. Learn more at CarisDetect.com

What if an H&E slide could tell us more about a patient’s risk of breast cancer recurrence? Artificial intelligence is opening that door. New research from the ECOG-ACRIN Cancer Research Group and Caris Life Sciences provides evidence for the image + clinical AI approach that helped lay the scientific foundation for Caris MI Clarity™ in HR+/HER2− early-stage breast cancer. In an independent TAILORx validation cohort, an AI model combining H&E-derived image features with clinical information strongly distinguished between patients at higher versus lower risk of early distant recurrence. That image + clinical approach subsequently evolved into Caris MI Clarity, bringing AI-powered recurrence risk assessment into clinical practice. Learn more: ow.ly/bS5W5102bkL